TipRanks
Advertisement
Advertisement

DE:AXD2 Stock Latest News

Heron Therapeutics Expands U.S. Portfolio Through Licensing Deal
Company AnnouncementsHeron Therapeutics Expands U.S. Portfolio Through Licensing Deal
7d ago
8K
HRTX
Heron Therapeutics enters license agreement with Long Grove, Capstone
PremiumThe Fly
Heron Therapeutics enters license agreement with Long Grove, Capstone
7d ago
HRTX
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
8d ago
YSS
DPRO
Heron Therapeutics Earnings Call: Growth Meets New Risks
PremiumCompany Announcements
Heron Therapeutics Earnings Call: Growth Meets New Risks
2M ago
HRTX
Heron Therapeutics Extends Tax Benefit Preservation Plan Timeline
PremiumCompany Announcements
Heron Therapeutics Extends Tax Benefit Preservation Plan Timeline
2M ago
8K
HRTX
Heron Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe FlyHeron Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
2M ago
HRTX
Heron Therapeutics Faces Nasdaq Delisting Risk as Share Price Falls Below $1 Threshold
Premium
Company Announcements
Heron Therapeutics Faces Nasdaq Delisting Risk as Share Price Falls Below $1 Threshold
2M ago
HRTX
HRTX Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
HRTX Upcoming Earnings Report: What to Expect?
2M ago
HRTX
Heron Therapeutics Faces Nasdaq Minimum Bid Price Deficiency
PremiumCompany Announcements
Heron Therapeutics Faces Nasdaq Minimum Bid Price Deficiency
3M ago
8K
HRTX
Heron Shareholders Approve Directors, Incentive Plans, Tax Measures
PremiumCompany Announcements
Heron Shareholders Approve Directors, Incentive Plans, Tax Measures
4M ago
8K
HRTX
Heron Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
PremiumThe Fly
Heron Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
4M ago
HRTX
Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents
PremiumCompany Announcements
Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents
4M ago
8K
HRTX
Heron Therapeutics downgraded at Needham after Cinvanti patents invalidated
PremiumThe FlyHeron Therapeutics downgraded at Needham after Cinvanti patents invalidated
4M ago
HRTX
Heron Therapeutics downgraded to Hold from Buy at Needham
Premium
The Fly
Heron Therapeutics downgraded to Hold from Buy at Needham
4M ago
HRTX
Heron announces U.S. district court decision regarding Cinvanti patents
Premium
The Fly
Heron announces U.S. district court decision regarding Cinvanti patents
4M ago
HRTX
Heron Therapeutics Faces Tight Covenant Constraints That Threaten Liquidity and Strategic Flexibility
PremiumCompany Announcements
Heron Therapeutics Faces Tight Covenant Constraints That Threaten Liquidity and Strategic Flexibility
5M ago
HRTX
Heron Therapeutics Signals Recovery Despite Soft Q1
PremiumCompany Announcements
Heron Therapeutics Signals Recovery Despite Soft Q1
5M ago
HRTX
Heron Therapeutics price target lowered to $4 from $6 at H.C. Wainwright
PremiumThe Fly
Heron Therapeutics price target lowered to $4 from $6 at H.C. Wainwright
5M ago
HRTX
Heron Therapeutics reports Q1 EPS (4c), consensus (2c)
PremiumThe Fly
Heron Therapeutics reports Q1 EPS (4c), consensus (2c)
5M ago
HRTX
Heron Therapeutics backs FY26 revenue view $173M-$183M, consensus $174.73M
PremiumThe FlyHeron Therapeutics backs FY26 revenue view $173M-$183M, consensus $174.73M
5M ago
HRTX
HRTX Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
HRTX Earnings this Week: How Will it Perform?
5M ago
HRTX
Heron Therapeutics (HRTX): Buy Rating on Expanding Hospital Product Adoption and Attractive Risk‑Reward
Premium
Ratings
Heron Therapeutics (HRTX): Buy Rating on Expanding Hospital Product Adoption and Attractive Risk‑Reward
6M ago
HRTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >